OncLive TV

Dr. Michael J. Overman on Immunotherapy in Colorectal Cancer

August 19th 2016

Dr. Kay on Genetic Investigations in Chronic Lymphocytic Leukemia

August 18th 2016

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the genetic investigations being conducted in chronic lymphocytic leukemia (CLL), and more specifically, monoclonal b-cell lymphocytosis, which resembles CLL but does not meet the same criteria.

Dr. Rudin on Rova-T in Patients With Small Cell Lung Cancer

August 18th 2016

Charles M. Rudin, MD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T) in patients with recurrent or refractory small cell lung cancer (SCLC).

Dr. Hudis on Combating Obesity in Breast Cancer

August 18th 2016

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

August 18th 2016

Patient Resistance to Swallowing Exercises After Multimodality Therapy

August 17th 2016

Giselle Carnaby, PhD, professor, ASHA fellow, Communication Sciences and Disorders, University of Central Florida, discusses rehabilitation of swallowing after multimodality therapy in patients with head and neck cancer, and why they may be resistant to it.

Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple Myeloma

August 17th 2016

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Joyce O'Shaughnessy on Promising Agents in Triple-Negative Breast Cancer

August 17th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.

Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

August 17th 2016

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

August 17th 2016

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

August 17th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

Dr. Paty on Patients With Rectal Cancer Ineligible for "Watch and Wait"

August 17th 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL

August 16th 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Shaji Kumar on Upfront Combination Treatments in Multiple Myeloma

August 16th 2016

​Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.

Dr. Fishman Discusses Available Agents to Treat Patients With RCC

August 16th 2016

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

August 12th 2016

Dr. Michele Cavo on ASCT Role in Novel-Agent Era of Multiple Myeloma

August 12th 2016

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses the role of upfront autologous stem cell transplantation (ASCT) in multiple myeloma.

Dr. Pecora on How the OCM Will Transform Operations For His Physician Group

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Dr. Pecora on Patient Management Payments Under the OCM

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.